Skip to main content

Redefining the discovery and development of best-in-class oligonucleotide therapeutics

Our Mission

With OligoCreator®, our AI-empowered drug discovery platform, we deliver on our mission to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

About us

We redefine the discovery and development of best-in-class oligonucleotide therapeutics. With our AI-empowered OligoCreator® platform, which integrates a variety of delivery technologies, we identify and characterize oligonucleotide therapeutics with unparalleled speed and excellent safety and efficacy. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapies have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders. Our unique OligoCreator® platform is leveraged to transform untreatable conditions into treatable ones, profoundly changing the future of medicine.

Mode of Action

Latest News & Events

March 26, 2025

Secarna Pharmaceuticals to present positive new data on antisense oligonucleotide SECN-15 targeting NRP1 as monotherapy and in combination with immune checkpoint inhibitors at AACR

  • Data will showcase SECN-15’s potential to significantly improve the efficacy of immune checkpoint inhibitors
  • Secarna is preparing for first-in-human trials to start mid-2026 to further explore this promising combination therapeutic strategy

 

October 31, 2024

Secarna Announces Appointment of Konstantin Petropoulos as Chief Executive Officer

Martinsried (Munich), Germany, October 31, 2024 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics today announced the promotion of Konstantin Petropoulos, PhD, MBA, to Chief Executive Officer.  He has served as the Company’s Chief Business Officer since June 2023.  Alexander Gebauer, MD, PhD, is stepping down with immediate effect to focus his efforts on another company, Galimedix Therapeutics, that he has co-founded and is leading. He will continue to support Dr. Petropoulos in his new role to ensure a smooth transition. 

September 09, 2024

Secarna Pharmaceuticals will present data at 6th Inflammasome Therapeutics Summit demonstrating the potential of ASOs to target the expression of NLRP3

  • NLRP3 is a promising target with a well-validated role in various inflammatory disease
  • Secarna has shown the potential of the company’s ASOs to effectively and specifically suppress NLRP3 and IL-1β release
  • In a CAPS mouse model, Secarna demonstrated prolonged survival and a significant reduction in systemic inflammation
April 3 - 5, 2025

11th Immunotherapy of Cancer Conference

Munich, Germany
April 25 - 30, 2025

American Association for Cancer Research (AACR) 2025

Chicago, IL, USA
May 12 - 14, 2025

Bio€quity Europe 2025

Bruges, Belgium

With our AI-empowered OligoCreator® platform we streamline the identification and characterization of best-in-class oligonucleotide therapies to deliver transformative treatments and hope to patients in need by pushing the boundaries of medical science and transforming lives for the better.

Konstantin Petropoulos, Ph.D., MBA
CEO